CMPI.org

In the News

Peter Pitts on Healthcare Bill's Passage in US House

05/04/2017 12:00 AM | i24NEWS

Peter Pitts discusses progress of GOP Healthcare Bill on i24NEWS

04/21/2017 12:00 AM | i24NEWS

Making Drug Manufacturing Great Again

04/21/2017 12:00 AM | Investor's Business Daily

Peter Pitts on Fox News: How the pharmaceutical industry fits into the opioid crisis

04/11/2017 12:00 AM | Fox News

Peter Pitts on WOR 710 "In The Arena"

04/11/2017 12:00 AM | WOR 710

How Trump and the FDA Can Create a Pharmaceutical Manufacturing Renaissance

04/10/2017 12:00 AM | Morning Consult

ICER Devalues People With Rheumatoid Arthritis

03/29/2017 12:00 AM | LinkedIn

Peter Pitts on CNBC: Revised 'bottom up' US healthcare bill delayed

03/23/2017 12:00 AM | CNBC

Gottlieb Likely to Take On Off-Label, Predictability at the FDA

03/16/2017 12:00 AM | Medical Marketing & Media

CMPI President Peter J. Pitts discusses the American Health Care Act on i24News

03/14/2017 12:00 AM | i24NEWS

Peter Pitts discusses new GOP Healthcare Plan

03/09/2017 12:00 AM | i24NEWS

Pharmaceutical Industry Raises Issue with Cuomo's Drug Price Control Proposal

03/08/2017 12:00 AM | NY1 News Capital Tonight

U.N.'s errant prescription for drug access

02/27/2017 12:00 AM | Pittsburgh Tribune

How Other Countries Freeload on U.S. Drug Research

02/21/2017 12:00 AM | Wall Street Journal

Reduce drug prices by eliminating PBM rebates

02/15/2017 12:00 AM | The Hill

The Privacy Delusions Of Genetic Testing

02/15/2017 12:00 AM | Forbes

Controlling Cost Through Value

02/10/2017 12:00 AM | Morning Consult

President Trump misunderstands what government drug price negotiations entail

02/01/2017 12:00 AM | Washington Examiner

Keep the feds out of drug pricing

12/18/2016 12:00 AM | USA Today

There is a Sure Cure, But It's Not Covered by Your Health Insurance Plan

09/17/2016 12:00 AM | Newsweek

Previous
1
...
4
5
6
7
8
9
Next

RECENT NEWS

Biosimilar Strength vs. Potency: Avoiding a Regulatory Hobson’s Choice

FDLI
09/07/2021 12:00 AM

Biosimilar Strength vs. Potency: Avoiding a Regulatory Hobson’s Choice

Biosimilars bring lower costs and greater access to the market for biological products, but FDA must determine a predicta... Read more

FDA Authorizes Pfizer Covid-19 Vaccine Booster for Ages 12-15

NEWSY
01/04/2022 12:00 AM

FDA Authorizes Pfizer Covid-19 Vaccine Booster for Ages 12-15

CMPI's Peter Pitts discusses FDA approval of Pfizer COVID vaccine booster for children ages 12-15... Read more

Should We Rethink The FDA Commissionership?

Health Affairs
12/22/2021 12:00 AM

Should We Rethink The FDA Commissionership?

When one considers the FDA’s mission—to independently protect consumers and advance the public health—it is not at all cl... Read more

Read all News